Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management
- PMID: 37357958
- DOI: 10.1002/ajh.27002
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management
Abstract
Disease overview: Polycythemia vera (PV) is a JAK2-mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and increased risk of thrombosis and progression into myelofibrosis (post-PV MF) or acute myeloid leukemia (AML).
Diagnosis: A working diagnosis is considered in the presence of a JAK2 mutation associated with hemoglobin/hematocrit levels of >16.5 g/dL/49% in men or 16 g/dL/48% in women; morphologic confirmation by bone marrow examination is advised but not mandated.
Cytogenetics: Abnormal karyotype is seen in 15%-20% of patients with the most frequent sole abnormalities being +9 (5%), loss of chromosome Y (4%), +8 (3%), and 20q- (3%).
Mutations: Over 50% of patients harbor DNA sequence variants/mutations other than JAK2, with the most frequent being TET2 (18%) and ASXL1 (15%). Prognostically adverse mutations include SRSF2, IDH2, RUNX1, and U2AF1, with a combined incidence of 5%-10%.
Survival and prognosis: Median survival is ⁓15 years but exceeds 35 years for patients aged ≤40 years. Risk factors for survival include older age, leukocytosis, abnormal karyotype, and the presence of adverse mutations. Twenty-year risk for thrombosis, post-PV MF, or AML are ⁓26%, 16% and 4%, respectively.
Risk factors for thrombosis: Two risk categories are considered: high (age >60 years or thrombosis history) and low (absence of both risk factors). Additional predictors for arterial thrombosis include cardiovascular risk factors and for venous thrombosis higher absolute neutrophil count and JAK2V617F allele burden.
Treatment: Current goal of therapy is to prevent thrombosis. Periodic phlebotomy, with a hematocrit target of <45%, combined with once- or twice-daily aspirin (81 mg) therapy, absent contraindications, is the backbone of treatment in all patients, regardless of risk category. Cytoreductive therapy is reserved for high-risk disease with first-line drugs of choice being hydroxyurea and pegylated interferon-α and second-line busulfan and ruxolitinib. In addition, systemic anticoagulation is advised in patients with venous thrombosis history.
Additional treatment considerations: At the present time, we do not consider a drug-induced reduction in JAK2V617F allele burden, which is often incomplete and seen not only with peg-IFN but also with ruxolitinib and busulfan, as an indicator of disease-modifying activity, unless accompanied by cytogenetic and independently-verified morphologic remission. Accordingly, we do not use the specific parameter to influence treatment choices. The current review also includes specific treatment strategies in the context of pregnancy, splanchnic vein thrombosis, pruritus, perioperative care, and post-PV MF.
© 2023 Wiley Periodicals LLC.
Similar articles
-
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38269572 Review.
-
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23. Am J Hematol. 2020. PMID: 32974939 Review.
-
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.Am J Hematol. 2019 Jan;94(1):133-143. doi: 10.1002/ajh.25303. Epub 2018 Nov 9. Am J Hematol. 2019. PMID: 30281843
-
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607. Am J Hematol. 2017. PMID: 27991718
-
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895. Am J Hematol. 2015. PMID: 25611051 Review.
Cited by
-
Histopathological Confirmed Polycythemia Vera with Transformation to Myelofibrosis Depicted on [18F]FDG PET/CT.Diagnostics (Basel). 2024 May 8;14(10):982. doi: 10.3390/diagnostics14100982. Diagnostics (Basel). 2024. PMID: 38786281 Free PMC article.
-
The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms.Clin Exp Med. 2024 May 22;24(1):107. doi: 10.1007/s10238-024-01371-7. Clin Exp Med. 2024. PMID: 38776019 Free PMC article.
-
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes.Ann Hematol. 2024 May 21. doi: 10.1007/s00277-024-05809-6. Online ahead of print. Ann Hematol. 2024. PMID: 38771499
-
Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century.Ann Hematol. 2024 Apr 9. doi: 10.1007/s00277-024-05723-x. Online ahead of print. Ann Hematol. 2024. PMID: 38592500 Review.
-
TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model.Front Oncol. 2024 Mar 22;14:1369346. doi: 10.3389/fonc.2024.1369346. eCollection 2024. Front Oncol. 2024. PMID: 38585007 Free PMC article.
References
REFERENCES
-
- Thiele J, Kvasnicka HM, Orazi A, et al. The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:166-179.
-
- Thiele J, Kvasnicka HM, Orazi A, et al. The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms. Am J Hematol. 2023;98:544-545.
-
- Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200-1228.
-
- Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for myelofibrosis research and treatment. Leukemia. 2008;22:437-438.
-
- Orazi A, Hasserjian RP, Cazzola M, Döhner H, Tefferi A, Arber DA. International consensus classification for myeloid neoplasms at-a-glance. Am J Hematol. 2023;98:6-10.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous